TUHH Open Research
Help
  • Log In
    New user? Click here to register.Have you forgotten your password?
  • English
  • Deutsch
  • Communities & Collections
  • Publications
  • Research Data
  • People
  • Institutions
  • Projects
  • Statistics
  1. Home
  2. TUHH
  3. Publication References
  4. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis : results from the EUROFORS study
 
Options

Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis : results from the EUROFORS study

Publikationstyp
Journal Article
Date Issued
2009-10-01
Sprache
English
Author(s)
Graeff, Christian  
Chevalier, Yan  
Charlebois, Mathieu  
Varga, Peter  
Pahr, Dieter  
Nickelsen, Thomas N.  
Morlock, Michael  
Glüer, Claus Christian  
Zysset, Philippe K.  
Institut
Biomechanik M-3  
TORE-URI
http://hdl.handle.net/11420/5438
Journal
Journal of bone and mineral research  
Volume
24
Issue
10
Start Page
1672
End Page
1680
Citation
Journal of Bone and Mineral Research 10 (24): 1672-1680 (2009)
Publisher DOI
10.1359/jbmr.090416
Scopus ID
2-s2.0-70349911489
Publisher
American Society for Bone and Mineral Research
Monitoring of osteoporosis therapy based solely on DXA is insufficient to assess antifracture efficacy. Estimating bone strength as a variable closely linked to fracture risk is therefore of importance. Finite element (FE) analysis-based strength measures were used to monitor a teriparatide therapy and the associated effects on whole bone and local fracture risk. In 44 postmenopausal women with established osteoporosis participating in the EUROFORS study, FE models based on high-resolution CT (HRCT) of T12 were evaluated after 0, 6, 12, and 24 mo of teriparatide treatment (20 μg/d). FE-based strength and stiffness calculations for three different load cases (compression, bending, and combined compression and bending) were compared with volumetric BMD (vBMD) and apparent bone volume fraction (app. BV/TV), as well as DXA-based areal BMD of the lumbar spine. Local damage of the bone tissue was also modeled. Highly significant improvements in all analyzed variables as early as 6 mo after starting teriparatide were found. After 24 mo, bone strength in compression was increased by 28.1 ± 4.7% (SE), in bending by 28.3 ± 4.9%, whereas app. BV/TV was increased by 54.7 ± 8.8%, vBMD by 19.1 ± 4.0%, and areal BMD of L1-L4 by 10.2 ± 1.2%. When comparing standardized increases, FE changes were significantly larger than those of densitometry and not significantly different from app. BV/TV. The size of regions at high risk for local failure was significantly reduced under teriparatide treatment. Treatment with teriparatide leads to bone strength increases for different loading conditions of close to 30%. FE is a suitable tool for monitoring bone anabolic treatment in groups or individual patients and offers additional information about local failure modes. FE variables showed a higher standardized response to changes than BMD measurements, but further studies are needed to show that the higher response represents a more accurate estimate of treatment-induced fracture risk reduction. © 2009 American Society for Bone and Mineral Research.
Subjects
Bone strength
CT
Finite element analysis
Osteoporosis
Teriparatide
DDC Class
610: Medizin
TUHH
Weiterführende Links
  • Contact
  • Send Feedback
  • Cookie settings
  • Privacy policy
  • Impress
DSpace Software

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science
Design by effective webwork GmbH

  • Deutsche NationalbibliothekDeutsche Nationalbibliothek
  • ORCiD Member OrganizationORCiD Member Organization
  • DataCiteDataCite
  • Re3DataRe3Data
  • OpenDOAROpenDOAR
  • OpenAireOpenAire
  • BASE Bielefeld Academic Search EngineBASE Bielefeld Academic Search Engine
Feedback